Aue G, Lindorfer MA, Beum PV, Pawluczkowycz AW, Vire B, Hughes T, Taylor RP, Wiestner A. Fractionated subcutaneous rituximab is well-tolerated and preserves CD20 expression on tumor cells in patients with chronic lymphocytic leukemia. Haematologica [Internet]. 2010Feb.5 [cited 2026Nov.13];95(2):329-32. Available from: https://haematologica.org/article/view/5506